The Case for GLP-1 Agonists: Why Tirzepatide and Its Cousins Are the Future of Obesity Care

For nearly a century, the medical response to obesity has amounted to a shrug dressed up as advice: eat less, move more, try harder. The data on how that worked out is unambiguous. U.S. adult obesity prevalence has climbed to roughly 41.9%, and obesity- and heart-failure-related deaths in the United States more than tripled between 1999 and 2024 [1]. The annual direct medical cost of obesity in the U.S. now sits around $173 billion, with broader economic impact estimates exceeding $1.4 trillion [1][2]. Lifestyle intervention alone produces ≥15% weight loss in fewer than 20% of patients, and most regain about a third of what they lose within a year [3].

Into this landscape walked GLP-1 receptor agonists, and more recently the dual GIP/GLP-1 agonist tirzepatide. The headlines have alternated between miracle and menace. The clinical evidence tells a more grounded story: these drugs are the most effective pharmacological tool we have ever had against obesity, their safety profile is well-characterized and broadly acceptable, and dismissing them as "dangerous" misreads both the data and the disease they treat.

Efficacy that rewrites the textbook

The SURMOUNT-1 trial randomized adults with obesity (without diabetes) to weekly tirzepatide or placebo for 72 weeks. Mean weight loss was 16% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus 2.4% on placebo. Between 89% and 96% of patients on tirzepatide lost at least 5% of body weight, compared with 29% on placebo [4]. To put that in perspective, bariatric surgery — the previous gold standard — typically delivers 25–30% weight loss. A weekly injection now approaches surgical outcomes.

SURMOUNT-3 added a 12-week intensive lifestyle lead-in before randomization, and patients on tirzepatide lost an additional 18.4% beyond their initial diet-and-exercise loss, compared with a 2.5% regain on placebo [3]. SURMOUNT-4 tested what happens when treatment stops: patients who stayed on tirzepatide kept losing weight (-5.5% over the next year), while those switched to placebo regained 14% [5]. That last finding is sometimes used as an indictment ("you have to take it forever!"), but it is actually how chronic disease therapy works. Nobody argues that statins fail because cholesterol rises when you stop them.

Benefits that go well beyond the scale

If GLP-1 agonists only moved the needle on weight, they would still be valuable. But the cardiovascular outcomes data has changed the conversation entirely. The SELECT trial randomized over 17,000 adults with overweight or obesity and established cardiovascular disease (but no diabetes) to semaglutide or placebo. The result: a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke), a 73% reduction in incident diabetes, and a 22% lower risk of renal outcomes [6][7]. The FDA approved semaglutide in March 2024 to reduce cardiovascular events in this population [7].

A meta-analysis of GLP-1 receptor agonist cardiovascular outcome trials in type 2 diabetes found a 12% reduction in all-cause mortality and a 13% reduction in cardiovascular mortality [8]. These are mortality benefits — actual lives saved — on top of weight loss, glucose control, and renal protection. Few drug classes in modern medicine can claim that breadth of benefit from a single intervention.

Tirzepatide's pleiotropic effects extend further: clinically meaningful improvements in obstructive sleep apnea, MASH (metabolic dysfunction-associated steatohepatitis), heart failure with preserved ejection fraction, and quality-of-life measures have all been documented in the SURMOUNT program and adjacent trials [9][10].

Putting the safety profile in context

The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, decreased appetite — and they are mild to moderate in most patients, dose-dependent, and decline over time as patients titrate up [11][12]. A systematic review of tirzepatide safety concluded the profile is generally acceptable and broadly comparable to that of GLP-1 receptor agonists already in use for nearly two decades [12].

Yes, there are real concerns that deserve naming. Tirzepatide carries a boxed warning for medullary thyroid carcinoma based on rodent data, and FAERS post-marketing analysis did detect a disproportional reporting signal — though tirzepatide's signal was similar to other GLP-1 RAs and not elevated above the class [11]. Pancreatitis and gallbladder disease appear at modestly increased rates [11]. European regulators have investigated reports of suicidal ideation, though large pharmacovigilance analyses have so far not established a causal link, and reported psychiatric adverse events represent a small fraction of total reports [13]. Muscle mass loss accompanies any rapid weight loss and warrants attention to protein intake and resistance training, but is not unique to these drugs.

The honest comparison is not "GLP-1s vs. a risk-free alternative." It is "GLP-1s vs. untreated obesity," a condition that drives heart disease, stroke, type 2 diabetes, multiple cancers, sleep apnea, osteoarthritis, and shortened life expectancy. Estimates suggest BMI increases between 1988 and 2011 alone cut nearly a year off life expectancy at age 40 [14]. The relevant question is whether the drug's risks exceed those of the disease it treats. For most eligible patients, they don't come close.

The paradigm shift

Obesity has long been treated as a moral failing dressed in clinical language. The arrival of GLP-1 agonists — and especially the dual-receptor tirzepatide — has forced a reframing: obesity behaves like a chronic, biologically-driven disease, and it responds to chronic, biologically-targeted therapy. That is not a marketing slogan; it is the most parsimonious explanation for why a weekly injection accomplishes what a century of willpower-based interventions could not.

The pipeline ahead — oral GLP-1s, triple agonists, longer-acting formulations — suggests we are at the beginning of this story, not the end. Cost and access remain genuine problems, and long-term (10+ year) data is still being accumulated. But the answer to those problems is broader coverage, more competition, and continued post-marketing surveillance — not retreat from the most effective obesity treatment ever developed.

A note on the other side of the argument

A balanced reader should weigh several legitimate counterpoints: long-term (decade-plus) safety data does not yet exist for tirzepatide; the requirement for indefinite use raises questions about lifetime cost and adherence; muscle and bone density loss during rapid weight reduction need active management; access disparities risk widening health inequities; and rare but serious adverse events (severe gastroparesis, pancreatitis, gallbladder disease) are not zero. Pharmacovigilance signals around psychiatric effects warrant continued monitoring. None of these undo the case above, but a treatment this powerful deserves clear-eyed monitoring rather than uncritical enthusiasm.

References

[1] Rising Trends in Obesity and Heart Failure: Related Mortality in the United States, 1999–2024. PMC12615744. https://pmc.ncbi.nlm.nih.gov/articles/PMC12615744/

[2] Obesity Medicine Association. How Much Does Obesity Cost the U.S? https://obesitymedicine.org/blog/health-economic-impact-of-obesity/

[3] Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, 2024. https://www.nature.com/articles/s41591-023-02597-w

[4] Jastreboff AM et al. SURMOUNT-1 results, summarized in: Tirzepatide for overweight and obesity management. Expert Opinion on Pharmacotherapy, 2024. https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2436595

[5] Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/

[6] Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM, 2023. Summarized in PMC11439431. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439431/

[7] U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial. PMC12277595. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277595/

[8] Cardiovascular and microvascular outcomes of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis. PMC6142638. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142638/

[9] Tirzepatide for overweight and obesity management. Expert Opinion on Pharmacotherapy, 2024. https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2436595

[10] Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4. PMC12559773. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12559773/

[11] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. PMC11473560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473560/

[12] A systematic review of the safety of tirzepatide — a new dual GLP1 and GIP agonist. PMC10084319. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084319/

[13] Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of EudraVigilance. PMC10960895. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10960895/

[14] U.S. Joint Economic Committee, The Social Cost of Obesity, 2023 Report, Chapter 3. https://www.jec.senate.gov/public/_cache/files/d1774be7-8a29-4ecc-996d-3bda421310f3/2023-erp-ch3-republican-response.pdf